These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6813486)

  • 21. [Experiences to date with oral gold therapy].
    Zeidler H
    Wien Klin Wochenschr Suppl; 1984; 156():22-7. PubMed ID: 6442052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multicentric ambulatory trial of Trolovol (D-penicillamine) in chronic polyarthritis].
    Tautz VI
    Z Rheumatol; 1975; 34(3-4):87-93. PubMed ID: 806188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Auranofin in the treatment of juvenile rheumatoid arthritis.
    Giannini EH; Brewer EJ; Person DA
    J Pediatr; 1983 Jan; 102(1):138-41. PubMed ID: 6401327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penicillamine and other remittive agents in rheumatoid arthritis: comparisons and interaction.
    Stein HB; Ruedy J; Atkins CJ; Offer RC
    Clin Invest Med; 1984; 7(1):59-63. PubMed ID: 6723126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of levamisole in rheumatoid arthritis: Immune changes and long-term results.
    Feldmann JL; Mery C; Amor B; Kahan A; de Gery A; Delbarre F
    Scand J Rheumatol; 1981; 10(1):1-8. PubMed ID: 7013056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of auranofin dose regimen change upon cell-associated gold in rheumatoid arthritic patients.
    Walz DT; Griswold DE; DiMartino MJ; Bumbier EE
    J Rheumatol; 1981; 8(5):829-32. PubMed ID: 6796684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-rheumatic drugs and joint damage in rheumatoid arthritis.
    Scott DL; Dawes PT; Fowler PD; Grindulis KA; Shadforth M; Bacon PA
    Q J Med; 1985 Jan; 54(213):49-59. PubMed ID: 3919415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
    Stone M; Fortin PR; Pacheco-Tena C; Inman RD
    J Rheumatol; 2003 Oct; 30(10):2112-22. PubMed ID: 14528503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Indications and contraindications for systemic gold therapy].
    Schattenkirchner M
    Wien Klin Wochenschr Suppl; 1984; 156():3-7. PubMed ID: 6442054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Preliminary results of oral gold treatment with auranofin following lack of success of intramuscular gold therapy].
    Rainer F; Ulreich A
    Wien Klin Wochenschr Suppl; 1984; 156():49-51. PubMed ID: 6442058
    [No Abstract]   [Full Text] [Related]  

  • 33. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cigarette smoking and the clinical outcome of gold therapy in rheumatoid arthritis.
    Lewis D; Capell HA; McNeil CJ; Smith WE; Brown DH
    J Rheumatol; 1984 Feb; 11(1):111-2. PubMed ID: 6422040
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis.
    Wolfe F
    J Rheumatol; 1997 Aug; 24(8):1477-85. PubMed ID: 9263138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Auranofin: more than just oral gold.
    Waller ES
    Clin Pharm; 1984; 3(2):195. PubMed ID: 6426845
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparative study of the effects of auranofin and aurothiomalate on laboratory and clinical indicators in patients with rheumatoid arthritis].
    Vlak T; Stambuk B
    Reumatizam; 1998; 46(1):7-19. PubMed ID: 9921004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness.
    Wolfe F; Pincus T
    J Rheumatol; 2001 Aug; 28(8):1817-24. PubMed ID: 11508584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ; Wells G; Verhoeven AC; Felson DT
    Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal disease activity for rheumatoid arthritis: a preliminary definition.
    Wells GA; Boers M; Shea B; Brooks PM; Simon LS; Strand CV; Aletaha D; Anderson JJ; Bombardier C; Dougados M; Emery P; Felson DT; Fransen J; Furst DE; Hazes JM; Johnson KR; Kirwan JR; Landewé RB; Lassere MN; Michaud K; Suarez-Almazor M; Silman AJ; Smolen JS; Van der Heijde DM; van Riel PL; Wolfe F; Tugwell PS
    J Rheumatol; 2005 Oct; 32(10):2016-24. PubMed ID: 16206362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.